Abstract | Background: Many infections due to Gram-positive cocci (GPC; staphylococci, streptococci and enterococci) regularly involve prolonged systemic antibiotic use. Dalbavancin has demonstrated activity against GPC isolates and has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. Objectives: To evaluate the activity of dalbavancin against GPC isolated from a variety of infection types in the USA and Europe. Methods: A total of 14 319 Staphylococcus aureus, 1992 CoNS, 3269 β-haemolytic streptococci (BHS), 2071 Enterococcus faecalis, 936 Enterococcus faecium, 71 Enterococcus gallinarum/casseliflavus and other Enterococcus spp., 3487 Streptococcus pneumoniae and 1063 viridans group streptococci (VGS) causing clinical infections were consecutively collected (2015-16) and tested for susceptibility by broth microdilution methods. Results: Conclusions:
|
Authors | Michael A Pfaller, Rodrigo E Mendes, Leonard R Duncan, Robert K Flamm, Helio S Sader |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 73
Issue 10
Pg. 2748-2756
(10 01 2018)
ISSN: 1460-2091 [Electronic] England |
PMID | 29982565
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Teicoplanin
- Vancomycin
- dalbavancin
- Daptomycin
|
Topics |
- Anti-Bacterial Agents
(pharmacology)
- Daptomycin
(pharmacology)
- Enterococcus
(drug effects, isolation & purification)
- Enterococcus faecalis
(drug effects, isolation & purification)
- Europe
(epidemiology)
- Gram-Positive Bacterial Infections
(epidemiology, microbiology)
- Gram-Positive Cocci
(drug effects, isolation & purification)
- Humans
- Microbial Sensitivity Tests
- Teicoplanin
(analogs & derivatives, pharmacology)
- United States
(epidemiology)
- Vancomycin
(pharmacology)
- Viridans Streptococci
(drug effects, isolation & purification)
|